Abstract

LASMIDITAN FOR THE TREATMENT OF ACUTE MIGRAINE: A REVIEW

Krishnananda Kamath K., Saleema Mariam* and A. R. Shabaraya

.

Abstract

Migraine is a neurological and disabling disease and is ranked as the world's second leading cause of disability. The primary goal of therapy is to alleviate pain, restore normal functions, reduce headache frequency, and consequently eliminate migraine-related symptoms. Triptans (selective 5-HT1B/D agonists) are considered first-line therapy for acute migraine attacks. Although triptans are effective for acute migraine abortive treatment, a significant number of individuals do not respond, and these medicines are also contraindicated in cardiovascular (CV) conditions due to their vasoconstrictive effects. As a result, novel effective anti-migraine therapies with no cardiovascular adverse effects, such as selective 5-HT1F receptor agonists, are necessary (ditans). In recent years, there have been significant advances in migraine management and prevention. On October 11, 2019, the US FDA approved lasmiditan, the first serotonin (5-HT) 1F receptor agonist, for the acute treatment of migraine, with and without aura, in adults. It is the first neurally acting antimigraine drug, and has no vasoconstrictive activity. Several Phase II and III trials have demonstrated superiority over placebo as well as the absence of typical triptan-associated adverse events (AEs). In this review, we discussed the current knowledge about Lasmiditan and its pharmacological profile, as well as summarised safety and efficacy data from basic research and clinical trials.

Keywords: Migraine, 5-HT1F, Lasmiditan, triptans, treatment.